Can a gout drug protect kidneys and arteries?

NCT ID NCT06997952

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether febuxostat, a drug that lowers uric acid, can slow the progression of chronic kidney disease and reduce thickening of the carotid artery wall. Adults with moderate-to-severe kidney disease and high uric acid levels will take febuxostat or standard care for 12 weeks. Researchers will measure changes in kidney function, protein in the urine, and artery thickness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a drug called febuxostat, which lowers uric acid levels
What this could lead to
If it works, febuxostat could offer a way to slow kidney disease progression and reduce cardiovascular risk in people with chronic kidney disease.
What could go wrong
This is a small, early-phase trial with only 50 participants and a short 12-week duration. The results may not apply to everyone, and febuxostat can cause side effects like allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAROTID INTIMA- MEDIA THICKNESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ain Shams University

    Cairo, Egypt, 11111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.